About Zymeworks Inc.
Developing novel medicines for patients with difficult-to-treat cancers and other serious diseases.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Vancouver, BC
- Founded
- 2003
- Company type
- Public Company
Zymeworks is a global biotechnology company developing and managing a portfolio of differentiated biotherapeutics to improve the standard of care for patients with difficult-to-treat cancers and autoimmune diseases. Leveraging our proprietary antibody engineering platforms, we are advancing a diverse pipeline of multispecific antibodies and antibody-drug conjugates, alongside partnered programs including Ziihera® (zanidatamab-hrii). Our integrated R&D engine and strategic partnerships enable the novel design of next-generation antibody therapeutics addressing significant unmet medical need.
Specialties
- antibody therapeutics
- bispecific antibodies
- ADC
- Breast Cancer
- Gastric Cancer
- protein engineering
- Biliary Tract Cancer
- autoimmune diseases
- inflammatory diseases
- t cell engagers
- and multispecific antibody therapeutics
Company locations
114 E 4th Avenue, Suite 800, Vancouver, BC V5T1G4, CA
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
On LinkedIn
- Followers
- 36,489
- People linked to this company
- 270
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.